Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical trial of CS-1002 in China

Trial Profile

Clinical trial of CS-1002 in China

Planning
Phase of Trial: Phase I

Latest Information Update: 10 May 2018

At a glance

  • Drugs CS-1002 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 10 May 2018 New trial record
    • 04 May 2018 According to a CStone Pharmaceuticals media release, the China Food and Drug Administration (CFDA) accepted the IND filing for CS-1002 in March 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top